We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Automated Immunoassay for HTLV I/II Antibodies Now Available

By LabMedica International staff writers
Posted on 05 Aug 2015
Image: The Elecsys benchtop analyzer was designed for small to medium workloads (Photo courtesy of Roche).
Image: The Elecsys benchtop analyzer was designed for small to medium workloads (Photo courtesy of Roche).
An automated immunoassay for the detection of antibodies against human T-lymphotropic virus I or II (HTLV-I/II) in donated blood and routine diagnostic samples and is now available for use by blood centers and clinical laboratories.

The Roche (Basel, Switzerland) HTLV-I/II immunoassay was designed for use on the Elecsys benchtop analyzer. This IVD instrument is powered by enhanced chemiluminescence (ECL) technology, which provides precise and reliable patient results that contribute to better patient care.

The Elecys instrument uses two electrochemically active substances, a ruthenium complex and tripropylamine (TPA). These reagents are involved in the reaction that leads to the emission of light. Ruthenium and TPA are non-isotopic and highly stable at base state. Only when voltage is applied and the labeled compound is repeatedly excited do the reactants begin emitting photons. To start the reaction, voltage is applied between the working and counter electrode, and an electrical field is created, ensuring a precisely controlled and timed reaction.

The operation is performed on a solution containing sample and reagents that are aspirated into the measuring cell. A magnetic field is applied, and the paramagnetic beads (coated with antigen/antibody complexes bound by streptavidin-biotin) are bound to the surface of the measuring cell. ProCell solution is introduced in order to separate the bound immunoassay complexes from the free remaining particles and to provide TPA, which is essential for the ECL-reaction. The test procedure requires about 18 minutes to run a single test.

“Globally there are around 20 million people infected with HTLV-I/II, many of whom are unknown carriers. If the virus is undetected in donors, the risk of spreading the infection increases,” said Roland Diggelmann, COO of the Roche Diagnostics Division. “Roche is uniquely positioned to help blood centers improve their testing efficiency, based on our broad assay portfolio and integrated molecular and serology laboratory solutions.”

Related Links:
Roche

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA

Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
ADLM